The University of Texas MD Anderson Cancer Center Houston, Texas
The University of Texas MD Anderson Cancer Center (MD Anderson) was established by the Texas State Legislature in 1941. In 1971, after the passage of the National Cancer Act, MD Anderson became one of the nation’s first NCI-designated comprehensive cancer centers.
MD Anderson is a free-standing, degree-granting component of the University of Texas System. The Center’s mission areas include patient care, research, education, and prevention. MD Anderson’s strength lies in its ability to rapidly translate scientific knowledge into better cancer therapies and prevention strategies.
In this area, there is an emphasis on cancer control and prevention trials. For example, MD Anderson administers an NCI-funded Community Clinical Oncology Program (CCOP) Research Base, which designs cancer control and prevention trials. These trials are then made available to a national network of sites so that patients can have access to state-of-the-art cancer care and clinical protocols without having to relocate temporarily or leave the support of their communities.
The Center is undergoing a period of remarkable growth. Its workforce of about 19,000 includes nearly 1,500 full-time faculty. More than 6,000 students take part each year in educational programs, including advanced degrees in biomedical sciences and bachelor’s degrees in allied health disciplines. MD Anderson’s main campus in Houston is supplemented by two research campuses in Bastrop County, Texas. The Center has also developed a number of local, national, and international affiliations.
MD Anderson is expanding its research with the creation of the McCombs Institute for the Early Detection and Treatment of Cancer. Composed of seven centers, the McCombs Institute focuses on genomics, proteomics, screening, RNA interference and non-coding RNAs, diagnostic imaging, and drug development.
Additionally, MD Anderson has created the Duncan Family Institute for Cancer Prevention and Risk Assessment to help accelerate the transfer of discoveries in prevention and genetic and lifestyle risk factor research to clinical and community settings.
In 2009, more than 96,000 patients were seen at MD Anderson. In late 2010, it will begin operating an additional 12 floors atop its Alkek Hospital, adding more than 300 inpatient beds to the current complement of 500. The Center was engaged in more than 1,000 active clinical trial protocols in 2009, with more than 11,000 patients taking part in trials of novel potential therapies.
* This profile was provided by the University of Texas MD Anderson Cancer Center.